Investigating how Losartan affects attention control using eye-tracking

The Effects of Losartan on Attention Control: An Eye-tracking Study

This study is testing if a single dose of Losartan can change how healthy people pay attention to social and emotional cues compared to a placebo.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 80 (estimated)
• Ages: 18 Years to 40 Years
• Sex: All
• Sponsor: University of Electronic Science and Technology of China (Academic / other)
• Locations: 1 site (Chengdu, Sichuan)
• Trial ID: NCT06329050 on ClinicalTrials.gov

What this trial studies

This study aims to explore the effects of Losartan, an angiotensin II antagonist, on attentional control towards socio-emotional stimuli in healthy individuals. Participants will receive either a single oral dose of Losartan or a placebo and then perform a saccade/anti-saccade eye-tracking task designed to assess their attentional responses to various social and non-social stimuli. The study employs a double-blind, randomized, placebo-controlled design to ensure the reliability of the findings. By examining both bottom-up and top-down attentional processes, the research seeks to understand the cognitive effects of Losartan.

Who should consider this trial

Good fit: Ideal candidates for this study are healthy individuals who can provide informed consent and have normal or corrected vision.

Not a fit: Patients with a history of neuropsychiatric, cardiac, hepatic, or renal diseases, as well as those with hypertension or hypotension, may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide insights into cognitive enhancement strategies for attention control using Losartan.

How similar studies have performed: While there is preliminary evidence suggesting neuroprotective effects of Losartan, this specific approach using eye-tracking is relatively novel and has not been extensively tested.

Eligibility criteria

Inclusion Criteria:

Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent.

Normal or corrected-normal version

Exclusion Criteria:

* History of neuropsychiatric diseases.
* History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness.
* History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction.
* History of renal diseases, including renal stones or renal failure.
* History of hyponatremia(Serum sodium \<135mmol/L) or hyperkalemia (Serum potassium\>5.5mmol/L); history of diabetes mellitus or diabetes insipidus
* Known hypersensitivity or allergic reaction to any medication or hormone; strong allergic reaction to food.
* Infections such as COVID-19 or influenza, or unexplained fever.
* Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg).
* History of alcohol or drug abuse; smoker (≥ 10 cigarettes or ≥ 3 cigars or ≥ 3 pipes/day); smoker using e-cigarettes.
* Blood donation (≤ 1 month prior to administration).
* Take oral contraceptives or receive hormonal medications in the three months prior to the experiment.
* Pregnant or breastfeeding.

Where this trial is running

Chengdu, Sichuan

• University of Electronic Science and Technology of China — Chengdu, Sichuan, China (Recruiting)

Study contacts

• Principal investigator: Benjamin Becker, Dr — University of Electronic Science and Technology of China
• Study coordinator: Weihua Zhao, Dr

Conditions Healthy; Eye-tracking; Losartan